A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumours
This phase II trial studies cediranib maleate in combination with olaparib in treating
patients with solid tumours that have spread to other parts of the body or cannot be removed
by surgery, including breast cancer, non-small cell lung cancer, small cell lung cancer, and
pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumour cells by
blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the
flow of oxygen to the tumour, and may help make the tumour more sensitive to olaparib.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society